Autres langues Actinium Pharmaceuticals, Inc.

Actions

ATNM

US00507W2061

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
1,010 ^USD	+1,00%		-8,18%	-25,74%

14/08	Actinium Pharmaceuticals renforce ses capacités de production pour le programme Actimab-A	CI
14/08	Actinium Pharmaceuticals, Inc. amende sa demande de nouveau médicament expérimental	CI

Autres langues

14/08	Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
14/08	Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program
14/08	Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug
07/08	Actinium: Q2 Earnings Snapshot
07/08	Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/06	Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
03/06	Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
03/06	Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors
01/06	Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
01/06	Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer
01/06	Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
01/06	Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
29/05	Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs
29/05	Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
29/05	Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
29/05	Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada
08/05	Actinium: Q1 Earnings Snapshot
08/05	Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
06/05	Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
22/04	Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML
22/04	Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting
22/04	Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
22/04	Actinium Pharmaceuticals : Preclinical Development of ATNM-400, a First-in-Class Actinium-225 Radioconjugate with Pan-Tumor Efficacy in Solid Tumors
22/04	Actinium Pharmaceuticals : Actimab-A, a CD33-Targeted Actinium-225 Radioconjugate, Drives Mutation-Agnostic Anti-Leukemic Activity and Synergizes with Standard Therapies in AML Through Transcriptional Reprogramming